SANOFI-ADR (SNY) Stock Fundamental Analysis
USA - NASDAQ:SNY - US80105N1054 - ADR
46.62 USD
-0.41 (-0.87%)
46.5049 USD
-0.12 (-0.25%)
Overall SNY gets a fundamental rating of 6 out of 10. We evaluated SNY against 196 industry peers in the Pharmaceuticals industry. SNY has an excellent profitability rating, but there are some minor concerns on its financial health. SNY may be a bit undervalued, certainly considering the very reasonable score on growth SNY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
SNY had a positive operating cash flow in the past year.
In the past 5 years SNY has always been profitable.
Each year in the past 5 years SNY had a positive operating cash flow.
1.2 Ratios
SNY has a better Return On Assets (11.05%) than 92.35% of its industry peers.
SNY has a Return On Equity of 19.73%. This is amongst the best in the industry. SNY outperforms 91.84% of its industry peers.
SNY has a Return On Invested Capital of 13.84%. This is amongst the best in the industry. SNY outperforms 92.35% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for SNY is significantly below the industry average of 15.28%.
The last Return On Invested Capital (13.84%) for SNY is above the 3 year average (7.31%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROIC | 13.84% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
1.3 Margins
SNY has a better Profit Margin (20.35%) than 93.37% of its industry peers.
SNY's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 23.59%, SNY belongs to the best of the industry, outperforming 90.31% of the companies in the same industry.
SNY's Operating Margin has improved in the last couple of years.
SNY has a Gross Margin of 71.70%. This is in the better half of the industry: SNY outperforms 79.08% of its industry peers.
In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% |
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
2. Health
2.1 Basic Checks
SNY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for SNY remains at a similar level compared to 1 year ago.
SNY has about the same amout of shares outstanding than it did 5 years ago.
SNY has a better debt/assets ratio than last year.
2.2 Solvency
SNY has a debt to FCF ratio of 2.21. This is a good value and a sign of high solvency as SNY would need 2.21 years to pay back of all of its debts.
SNY's Debt to FCF ratio of 2.21 is amongst the best of the industry. SNY outperforms 92.86% of its industry peers.
SNY has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
SNY has a Debt to Equity ratio (0.21) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Altman-Z | N/A |
ROIC/WACC1.93
WACC7.16%
2.3 Liquidity
A Current Ratio of 1.27 indicates that SNY should not have too much problems paying its short term obligations.
SNY has a worse Current ratio (1.27) than 74.49% of its industry peers.
SNY has a Quick Ratio of 1.27. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
SNY has a Quick ratio of 0.94. This is in the lower half of the industry: SNY underperforms 75.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -2.20% in the last year.
Measured over the past 5 years, SNY shows a small growth in Earnings Per Share. The EPS has been growing by 5.10% on average per year.
SNY shows a small growth in Revenue. In the last year, the Revenue has grown by 6.45%.
Measured over the past years, SNY shows a small growth in Revenue. The Revenue has been growing by 3.31% on average per year.
EPS 1Y (TTM)-2.2%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-8.09%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-6.99%
3.2 Future
SNY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.41% yearly.
SNY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.04% yearly.
EPS Next Y3.91%
EPS Next 2Y6.53%
EPS Next 3Y6.33%
EPS Next 5Y6.41%
Revenue Next Year-0.29%
Revenue Next 2Y3.32%
Revenue Next 3Y4.42%
Revenue Next 5Y4.04%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SNY is valuated reasonably with a Price/Earnings ratio of 10.48.
Based on the Price/Earnings ratio, SNY is valued cheaply inside the industry as 89.80% of the companies are valued more expensively.
SNY is valuated cheaply when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
SNY is valuated reasonably with a Price/Forward Earnings ratio of 9.08.
86.22% of the companies in the same industry are more expensive than SNY, based on the Price/Forward Earnings ratio.
SNY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.48 | ||
| Fwd PE | 9.08 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNY is valued cheaper than 97.45% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 91.84% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.63 | ||
| EV/EBITDA | 5.35 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SNY has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)2.68
PEG (5Y)2.06
EPS Next 2Y6.53%
EPS Next 3Y6.33%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 4.86%, which is a nice return.
SNY's Dividend Yield is rather good when compared to the industry average which is at 5.04. SNY pays more dividend than 96.43% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.38, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.86% |
5.2 History
The dividend of SNY has a limited annual growth rate of 4.30%.
SNY has been paying a dividend for at least 10 years, so it has a reliable track record.
The dividend of SNY decreased in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
SNY pays out 34.82% of its income as dividend. This is a sustainable payout ratio.
The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.82%
EPS Next 2Y6.53%
EPS Next 3Y6.33%
46.62
-0.41 (-0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.34%
Inst Owner Change-5.25%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap113.70B
Analysts80
Price Target64.8 (39%)
Short Float %0.2%
Short Ratio1.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.86% |
Yearly Dividend2.23
Dividend Growth(5Y)4.3%
DP34.82%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.86%
Min EPS beat(2)-2.29%
Max EPS beat(2)6.02%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-2.29%
Max EPS beat(4)14.5%
EPS beat(8)4
Avg EPS beat(8)2.17%
EPS beat(12)7
Avg EPS beat(12)2.71%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)3.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)9.26%
Revenue beat(16)8
Avg Revenue beat(16)21.08%
PT rev (1m)1.34%
PT rev (3m)-0.94%
EPS NQ rev (1m)-2.88%
EPS NQ rev (3m)-11.62%
EPS NY rev (1m)-4.12%
EPS NY rev (3m)-4.93%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-6.9%
Revenue NY rev (1m)-1.28%
Revenue NY rev (3m)-1.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.48 | ||
| Fwd PE | 9.08 | ||
| P/S | 1.43 | ||
| P/FCF | 9.63 | ||
| P/OCF | 8.53 | ||
| P/B | 1.39 | ||
| P/tB | 10.44 | ||
| EV/EBITDA | 5.35 |
EPS(TTM)4.45
EY9.55%
EPS(NY)5.13
Fwd EY11.01%
FCF(TTM)4.84
FCFY10.38%
OCF(TTM)5.47
OCFY11.73%
SpS32.62
BVpS33.64
TBVpS4.47
PEG (NY)2.68
PEG (5Y)2.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.05% | ||
| ROE | 19.73% | ||
| ROCE | 16.7% | ||
| ROIC | 13.84% | ||
| ROICexc | 16.48% | ||
| ROICexgc | 66.95% | ||
| OM | 23.59% | ||
| PM (TTM) | 20.35% | ||
| GM | 71.7% | ||
| FCFM | 14.83% |
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexcg growth 3Y-13.63%
ROICexcg growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-Score7
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 2.21 | ||
| Debt/EBITDA | 0.75 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 58.05% | ||
| Profit Quality | 72.91% | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 0.94 | ||
| Altman-Z | N/A |
F-Score7
WACC7.16%
ROIC/WACC1.93
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.2%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%-8.09%
EPS Next Y3.91%
EPS Next 2Y6.53%
EPS Next 3Y6.33%
EPS Next 5Y6.41%
Revenue 1Y (TTM)6.45%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-6.99%
Revenue Next Year-0.29%
Revenue Next 2Y3.32%
Revenue Next 3Y4.42%
Revenue Next 5Y4.04%
EBIT growth 1Y15.64%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year34.08%
EBIT Next 3Y14.6%
EBIT Next 5Y9.88%
FCF growth 1Y24.23%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y10.87%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%